日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer

III期炎性乳腺癌和非炎性乳腺癌的生存和治疗模式

Leone, José P; Leone, Julieta; De Placido, Pietro; Nakhlis, Faina; Schlam, Ilana; Hirko, Kelly A; Hazra, Aditi; Troll, Elizabeth; Bellon, Jennifer R; Vallejo, Carlos T; Lin, Nancy U; Tolaney, Sara M; Lynce, Filipa

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice

美国常规临床实践中,CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌患者的真实世界无进展生存期2(PFS2)和肿瘤反应

Rugo, Hope S; Brufsky, Adam; Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B; Estevez, Melissa; Lynce, Filipa; Cottu, Paul; Thill, Marc; Curigliano, Giuseppe

Implantation of engineered adipocytes suppresses tumor progression in cancer models.

植入工程化脂肪细胞可抑制癌症模型中的肿瘤进展

Nguyen Hai P, An Kelly, Ito Yusuke, Kharbikar Bhushan N, Sheng Rory, Paredes Breanna, Murray Elizabeth, Pham Kimberly, Bruck Michael, Zhou Xujia, Biellak Cassandra, Ushiki Aki, Nobuhara Mai, Fong Sarah L, Bernards Daniel A, Lynce Filipa, Dillon Deborah A, Magbanua Mark Jesus M, Huppert Laura A, Hammerlindl Heinz, Klein Jace Anton, Valdiviez Luis, Fiehn Oliver, Esserman Laura, Desai Tejal A, Yee Sook Wah, Rosenbluth Jennifer M, Ahituv Nadav

Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy

血清分析物作为预测三阴性乳腺癌患者疾病复发和无侵袭性疾病生存期的指标,这些患者均参与了 OXEL 试验,接受了免疫疗法、化疗或化疗联合免疫疗法治疗。

Toney, Nicole J; Lynch, Megan T; Lynce, Filipa; Mainor, Candace; Isaacs, Claudine; Schlom, Jeffrey; Donahue, Renee N

Clinicogenomic Characterization of Inflammatory Breast Cancer

炎性乳腺癌的临床基因组学特征分析

Priedigkeit, Nolan; Harrison, Beth; Shue, Robert; Hughes, Melissa E; Li, Yvonne; Lebrón-Torres, Alinés; Kirkner, Gregory J; Spurr, Liam F; Remolano, Marie Claire; Strauss, Sarah; Files, Janet; Feeney, Anne-Marie; Grant, Libby; Mohammed-Abreu, Ayesha; Garrido-Castro, Ana; Barroso-Sousa, Romualdo; Bychkovsky, Brittany; Nakhlis, Faina; Bellon, Jennifer R; King, Tari A; Winer, Eric P; Lindeman, Neal; Johnson, Bruce E; Sholl, Lynette; Dillon, Deborah; Overmoyer, Beth; Tolaney, Sara M; Cherniack, Andrew D; Lin, Nancy U; Lynce, Filipa

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods

帕博西尼联合芳香化酶抑制剂治疗居住在弱势社区的 HR+/HER2- 转移性乳腺癌患者的真实世界疗效

Lynce, Filipa; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Chen, Connie; Liu, Raymond; Rugo, Hope S

Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

建立多机构数据集以验证一种新型炎症性乳腺癌诊断评分

Lynce, Filipa; Niman, Samuel M; Kai, Megumi; Ryan, Sean; Troll, Elizabeth; Li, Li; Miller, Kathy D; Jagsi, Reshma; Mason, Ginny; Overmoyer, Beth A; Le-Petross, H T Carisa; Nakhlis, Faina; Krishnamurthy, Savitri; Harrison, Beth T; Sun, Susie X; Yeh, Eren D; Bellon, Jennifer R; Warren, Laura E; Stauder, Michael C; Regan, Meredith M; Woodward, Wendy A

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

艾立布林、多柔比星和环磷酰胺新辅助治疗HER2阴性炎性乳腺癌患者的II期研究

Fanucci, Kristina; Yeh, Eren D; Shi, Ruichao; Qin, Lei; Bay, Camden P; DiLullo, Molly; Patel, Ashka; Moore, McKenna; Herbert, Zachary T; Harrison, Beth T; Nakhlis, Faina; Bellon, Jennifer; Warren, Laura; Guerriero, Jennifer L; Tolaney, Sara M; Regan, Meredith; Overmoyer, Beth; Van Laere, Steven; Lynce, Filipa

Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study

Oncotype DX复发评分与HR阳性/HER2阴性早期乳腺癌患者的种系BRCA变异:一项回顾性观察研究

Morganti, Stefania; Khan, Rabia A; Berrocal-Almanza, Luis C; Miranda, Miguel; Luo, Linlin; Xu, Xiaoqing; Partridge, Ann H; Lynce, Filipa

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies

类器官可评估的临床生物标志物可预测药物反应并指导新的乳腺癌治疗

Bui, Tam Binh V; Wolf, Denise M; Bruck, Michael C; Moore, Kaitlin; Lien, Jessica; Choi, Sarah D W; Warhadpande, Shruti; Parizadeh, Amirabbas; Dillon, Deborah; Overmoyer, Beth; Lynce, Filipa; Nijman, Isaac J; Burgering, Boudewijn M T; Harris, Isaac S; Esserman, Laura J; Veer, Laura J van 't; Rosenbluth, Jennifer M